Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Cash from Financing Activities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Cash from Financing Activities for 6 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 2714.42% to -$2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$48.5 million through Dec 2025, down 120.35% year-over-year, with the annual reading at -$48.5 million for FY2025, 120.35% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$2.9 million at Lexicon Pharmaceuticals, up from -$45.0 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $239.4 million in Q1 2024, with the low at -$45.0 million in Q2 2025.
  • Average Cash from Financing Activities over 3 years is $34.3 million, with a median of -$210000.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities soared 29151.33% in 2024, then plummeted 321328.57% in 2025.
  • Over 3 years, Cash from Financing Activities stood at -$1000.0 in 2023, then tumbled by 10300.0% to -$104000.0 in 2024, then tumbled by 2714.42% to -$2.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$2.9 million, -$45.0 million, and -$572000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.